Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition...

詳細記述

保存先:
書誌詳細
出版年:Front Pharmacol
主要な著者: Ermisch, Michael, Bucsics, Anna, Vella Bonanno, Patricia, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Fürst, Jurij, Garuolienė, Kristina, van der Graaff, Martin, Gulbinovič, Jolanta, Haycox, Alan, Jones, Jan, Joppi, Roberta, Laius, Ott, Langner, Irene, Martin, Antony P., Markovic-Pekovic, Vanda, McCullagh, Laura, Magnusson, Einar, Nilsen, Ellen, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Sauermann, Robert, Schuurman, Ad, Ramos, Ricardo, Vlahovic-Palcevski, Vera, Zara, Corinne, Godman, Brian
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2016
主題:
Pharmacology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039228/
https://ncbi.nlm.nih.gov/pubmed/27733828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00305
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料